OX40 Agonists Forge a Path in Combination Immunotherapy – OncLive
OncLive |
OX40 Agonists Forge a Path in Combination Immunotherapy
OncLive The prospect of long-lasting responses and the hope of expanding its impact into unresponsive patient populations continue to make immuno-oncology a dynamic and exciting field. As our understanding of the antitumor immune response grows, so does the … |
